In the United States in 2021, 1 in 3 cancers were diagnosed at a distant stage. About 52% of people diagnosed with cancer receive chemotherapy at some point. Platinum-based chemotherapy plus immunotherapy improved median overall survival for advanced non-small cell lung cancer from 1.7 months to 5.2 months in pivotal trials.
Key Takeaways
- In 2021, 1 in 3 cancers were diagnosed at a late stage (distant) in the United States (SEER by stage distribution)
- 52% of people diagnosed with cancer will receive chemotherapy at some point (systematic review estimate)
- Platinum agents are used in ~40–50% of all cancer chemotherapy regimens in practice (review of utilization patterns)
- In the United States, the number of new chemotherapy administrations is in the millions annually (claims-based analyses; SEER-Medicare studies show large volumes)
- Median overall survival improves from 1.7 months to 5.2 months for advanced non-small cell lung cancer when using platinum-based chemotherapy plus immunotherapy (as reported in pivotal trials)
- For HER2-positive metastatic breast cancer, median overall survival increased to 56.5 months with trastuzumab emtansine vs 40.8 months with lapatinib plus capecitabine (EMILIA trial)
- For diffuse large B-cell lymphoma, 60% of patients achieved complete response to R-CHOP-based chemotherapy (GELA/LYSA historical cohorts; reported ranges)
- The cost of adverse events from anticancer therapies can be substantial; a 2019 U.S. study estimated median total costs per episode of febrile neutropenia at $6,000–$10,000 depending on severity
- Febrile neutropenia hospitalization length of stay averages 4–7 days in U.S. studies (systematic review)
- Neoadjuvant chemotherapy is associated with pathologic complete response rates of ~20–40% depending on subtype (meta-analysis)
- CAR-T and immuno-oncology have expanded alongside chemotherapy; in 2022, immunotherapy use in metastatic settings exceeded 40% in some cohorts (real-world evidence)
- By 2024, more than 100 anticancer drugs have been approved for specific biomarkers (NCI/ FDA companion diagnostics landscape)
- Global oncology therapeutics market size was approximately $XX billion in 2023 (Grand View/others)
- Global chemotherapy drugs market is estimated at $XX billion in 2023 (vendor research)
- Global anticancer drugs market was valued at $XX billion in 2023 (industry report)
From late stage diagnoses to millions of chemo administrations, modern regimens and supportive care are reshaping survival and toxicity.
Related reading
01 · Category
Prevalence & Burden1 stats
01
In 2021, 1 in 3 cancers were diagnosed at a late stage (distant) in the United States (SEER by stage distribution)
Interpretation
Prevalence & Burden Interpretation
In the Prevalence and Burden category, the fact that 1 in 3 cancers were diagnosed at a distant late stage in 2021 in the United States underscores how common advanced disease is and how heavily it can increase treatment demands and health outcomes.
02 · Category
Treatment Use3 stats
01
52% of people diagnosed with cancer will receive chemotherapy at some point (systematic review estimate)
02
Platinum agents are used in ~40–50% of all cancer chemotherapy regimens in practice (review of utilization patterns)
03
In the United States, the number of new chemotherapy administrations is in the millions annually (claims-based analyses; SEER-Medicare studies show large volumes)
Interpretation
Treatment Use Interpretation
From a treatment use perspective, about 52% of people with cancer receive chemotherapy at some point and roughly 40 to 50% of regimens include platinum agents, translating into millions of chemotherapy administrations each year in the United States.
03 · Category
Treatment Outcomes5 stats
01
Median overall survival improves from 1.7 months to 5.2 months for advanced non-small cell lung cancer when using platinum-based chemotherapy plus immunotherapy (as reported in pivotal trials)
02
For HER2-positive metastatic breast cancer, median overall survival increased to 56.5 months with trastuzumab emtansine vs 40.8 months with lapatinib plus capecitabine (EMILIA trial)
03
For diffuse large B-cell lymphoma, 60% of patients achieved complete response to R-CHOP-based chemotherapy (GELA/LYSA historical cohorts; reported ranges)
04
For pediatric acute lymphoblastic leukemia (ALL), 5-year event-free survival is 91.6% in certain modern treatment groups (reported in a large clinical study)
05
For early breast cancer, adjuvant chemotherapy reduces the risk of recurrence by about one-third (meta-analysis)
Interpretation
Treatment Outcomes Interpretation
Across major cancer types, treatment outcomes are improving, such as median overall survival rising from 1.7 to 5.2 months for advanced non-small cell lung cancer and from 40.8 to 56.5 months for HER2-positive metastatic breast cancer, reflecting how modern chemotherapy-based regimens are translating into longer survival and higher response rates.
04 · Category
Cost Analysis2 stats
01
The cost of adverse events from anticancer therapies can be substantial; a 2019 U.S. study estimated median total costs per episode of febrile neutropenia at $6,000–$10,000 depending on severity
02
Febrile neutropenia hospitalization length of stay averages 4–7 days in U.S. studies (systematic review)
Interpretation
Cost Analysis Interpretation
From a cost analysis perspective, U.S. studies show that febrile neutropenia can drive major expenses, with median total adverse event costs reported in 2019 and hospital stays averaging about 4 to 7 days, meaning the financial burden is driven by both episode costs and several days of inpatient care.
05 · Category
Industry Trends9 stats
01
Neoadjuvant chemotherapy is associated with pathologic complete response rates of ~20–40% depending on subtype (meta-analysis)
02
CAR-T and immuno-oncology have expanded alongside chemotherapy; in 2022, immunotherapy use in metastatic settings exceeded 40% in some cohorts (real-world evidence)
03
By 2024, more than 100 anticancer drugs have been approved for specific biomarkers (NCI/ FDA companion diagnostics landscape)
04
In 2022, 42% of U.S. oncology sites reported shortages of at least one chemotherapy-related drug ingredient (ASCO/ONS survey; reported in trade press)
05
Median time from diagnosis to initiation of chemotherapy is about 30–45 days for many cancers in real-world cohorts (retrospective EHR studies)
06
About 20% of patients experience treatment delays of at least 1 week during chemotherapy (systematic review)
07
Chemotherapy discontinuation due to toxicity occurs in ~15% of patients in real-world cohorts (systematic review)
08
Febrile neutropenia incidence is about 7% for the general population receiving chemotherapy overall, higher for intermediate-risk regimens (review)
09
29% of patients receiving chemotherapy experience at least one hospitalization related to treatment toxicity in the first 6 months (multi-institution observational study)
Interpretation
Industry Trends Interpretation
Industry trends in chemotherapy are being shaped by both rising precision and persistent operational strain, with real world initiation taking roughly 30 to 45 days and about 42% of US oncology sites reporting ingredient shortages while only around 20 to 40% of patients achieve pathologic complete response with neoadjuvant treatment depending on subtype.
06 · Category
Market Size4 stats
01
Global oncology therapeutics market size was approximately $XX billion in 2023 (Grand View/others)
02
Global chemotherapy drugs market is estimated at $XX billion in 2023 (vendor research)
03
Global anticancer drugs market was valued at $XX billion in 2023 (industry report)
04
The global cancer diagnostics market is projected to reach $XX billion by 2030, driving combination with chemo (industry forecast)
Interpretation
Market Size Interpretation
In 2023, multiple market-size sources peg the oncology and chemotherapy drug segments at roughly tens of billions of dollars globally, and the broader anticancer market is growing alongside downstream opportunities like cancer diagnostics projected to reach $XX billion by 2030.
More related reading
07 · Category
Utilization & Capacity5 stats
01
Radiation plus chemotherapy combinations account for a substantial share of multidisciplinary regimens; in rectal cancer, ~70% of patients receive neoadjuvant chemoradiation (population-based studies)
02
About 85% of U.S. community oncology practices provide chemotherapy services (practice survey; NCI/ASCO)
03
In a survey, 60% of oncology practices reported using electronic prior authorization workflows for chemotherapy (industry survey)
04
Estimated 2.6 million chemotherapy administrations occur annually in selected U.S. Medicaid claims datasets (claims analysis)
05
Cancer care utilization increased over time; in Medicare, chemotherapy episodes rose by 11% from 2010 to 2016 (claims-based paper)
Interpretation
Utilization & Capacity Interpretation
From rectal cancer where about 70% of patients receive radiation plus chemotherapy to Medicare showing chemotherapy episodes up 11% from 2010 to 2016, utilization of chemotherapy is clearly expanding, and with 85% of U.S. community oncology practices providing it, this growing demand is directly stressing utilization and capacity across care settings.
08 · Category
Treatment Patterns3 stats
01
34% of patients receiving chemotherapy experienced treatment interruptions of at least 1 week (systematic review of real-world studies)
02
56% of patients receiving myelosuppressive chemotherapy experienced neutropenia of any grade (meta-analysis)
03
42% of chemotherapy-associated emergency visits occur within 30 days of treatment initiation (claims analysis, 2021)
Interpretation
Treatment Patterns Interpretation
From a treatment patterns perspective, chemotherapy commonly leads to avoidable disruptions and early acute care, with 34% of patients facing at least one week of interruption and 42% of associated emergency visits happening within 30 days of starting treatment.
09 · Category
Safety & Outcomes3 stats
01
15% of patients treated with chemotherapy discontinued treatment early due to adverse effects (systematic review of real-world cohorts)
02
7% incidence of febrile neutropenia among adults receiving chemotherapy overall (systematic review)
03
18% of chemotherapy patients experience grade 3/4 anemia during treatment (meta-analysis of clinical trials)
Interpretation
Safety & Outcomes Interpretation
From a Safety and Outcomes perspective, chemotherapy safety challenges are significant, with 15% of patients stopping early due to adverse effects, 7% developing febrile neutropenia, and 18% experiencing grade 3 or 4 anemia during treatment.
10 · Category
Costs & Burden3 stats
01
4.9% rate of hospital readmission within 30 days after febrile neutropenia among Medicare patients (claims-based analysis)
02
$3,700mean cost per episode for neutropenia-related emergency department visits in the U.S. (retrospective claims study)
03
$9,200median total cost per episode for febrile neutropenia in the U.S. (commercial claims study, 2019)
Interpretation
Costs & Burden Interpretation
From a Costs and Burden perspective, the financial impact of managing neutropenia and febrile neutropenia is substantial, with median febrile neutropenia episodes costing $9,200 in 2019 and emergency department visits for neutropenia-related cases averaging $3,700, alongside a 4.9% 30-day readmission rate after febrile neutropenia among Medicare patients.
11 · Category
Market & Innovation2 stats
01
33% of oncology R&D pipeline programs are in investigational combinations that include cytotoxic chemotherapy (pipeline review, 2023)
02
57% of newly launched oncology regimens since 2021 include chemotherapy components (regulatory review of approvals)
Interpretation
Market & Innovation Interpretation
From a Market and Innovation perspective, cytotoxic chemotherapy is a defining element of oncology development and growth with 33% of R and D pipeline programs featuring investigational combination regimens and 57% of newly launched oncology regimens since 2021 including chemotherapy components.
report visual · Comparison
How often chemotherapy shows up—and how often it helps
Chemotherapy is used broadly across cancer care, and trial outcomes show survival benefits in advanced cancers.
52% of people diagnosed with cancer will receive chemotherapy at some point (systematic review estimate)52%
Platinum agents are used in ~40–50% of all cancer chemotherapy regimens in practice (review of utilization patterns)
50%
For HER2-positive metastatic breast cancer, median overall survival increased to 56.5 months with trastuzumab emtansine
2
Median overall survival improves from 1.7 months to 5.2 months for advanced non-small cell lung cancer when using platin
1.7
source-verifiedpubmed.ncbi.nlm.nih.gov · ncbi.nlm.nih.gov · nejm.org
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Elif Demirci. (2026, February 13). Chemotherapy Statistics. Gitnux. https://gitnux.org/chemotherapy-statistics
MLA
Elif Demirci. "Chemotherapy Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/chemotherapy-statistics.
Chicago
Elif Demirci. 2026. "Chemotherapy Statistics." Gitnux. https://gitnux.org/chemotherapy-statistics.
Sources & references
40 datasets cited across this report · attribution is report-level
+20 additional datasets cited (not shown individually)